XML 31 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 3 Months Ended 8 Months Ended 9 Months Ended 11 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating activities:                
Net loss     $ (29,154,000) $ (23,970,000)   $ (27,042,000) $ (17,557,000) $ (13,589,000)
Adjustments to reconcile net loss to net cash provided by operating activities:                
Change in estimated fair value of contingent liabilities     (487,000) (546,000)   1,210,000 2,070,000 (818,000)
Depreciation and amortization     13,429,000 13,779,000   16,252,000 13,137,000 10,917,000
Share-based compensation $ 5,279,000   12,273,000 11,605,000   15,065,000 9,165,000 6,660,000
Deferred income taxes, net     (6,840,000) (6,325,000)   (7,325,000) (6,185,000) 557,000
Gain from short-term investments           (1,265,000) 0 0
Gain from sale of intellectual property license           0 (1,900,000) 0
Other     (133,000) 35,000   64,000 161,000 0
Changes in operating assets and liabilities:                
Accounts receivable, net     17,610,000 12,721,000   6,019,000 339,000 (4,290,000)
Other current assets     (817,000) (188,000)   (632,000) (497,000) (14,000)
Other long-term assets     1,755,000 567,000   (938,000) 1,621,000 (20,000)
Accounts payable and accrued liabilities     432,000 161,000   1,513,000 2,759,000 (570,000)
Deferred revenue     (6,384,000) (5,118,000)   (6,717,000) 1,328,000 (1,875,000)
Other long-term liabilities     1,872,000 (3,953,000)   (1,876,000) (822,000) (2,153,000)
Net cash provided by (used in) operating activities     3,556,000 (1,232,000)   (5,672,000) 3,619,000 (5,195,000)
Investing activities:                
Purchase of property and equipment     (12,152,000) (2,548,000)   (4,070,000) (1,753,000) (255,000)
Payments to CVR holders     (960,000) 0   (720,000) 0 0
Proceeds from sale of short-term investments           1,265,000 0 0
Cash paid for acquisitions, net of cash and restricted cash acquired           0 (27,127,000) (11,840,000)
Proceeds from sale of intellectual property license           0 1,900,000 0
Other           (500,000) 0 0
Net cash used in investing activities     (13,112,000) (2,548,000)   (4,025,000) (26,980,000) (12,095,000)
Financing activities:                
Payment of offering costs     (4,183,000) 0        
Payments to CVR holders     (1,545,000) (1,050,000)   (1,050,000) (2,325,000) (3,000,000)
Deferred transaction cost payment     (4,183,000) 0        
Net transfer from parent     15,284,000 4,830,000   10,747,000 25,686,000 20,290,000
Net cash provided by financing activities     9,556,000 3,780,000   9,697,000 23,361,000 17,290,000
Net change in cash, cash equivalents and restricted cash     0 0   0 0 0
Cash, cash equivalents and restricted cash at beginning of period     0 0   0 0 0
Cash, cash equivalents and restricted cash at end of period 0 $ 0 0 0 $ 0 0 0 0
Supplemental disclosure of cash flow information:                
Deferred revenue recorded in accounts receivable           11,344,000 8,451,000 1,425,000
Purchase of fixed assets recorded in accounts payable     3,561,000 114,000   1,231,000 $ 0 $ 471,000
Avista Public Acquisition Corp. II [Member]                
Operating activities:                
Net loss   (180,550) (8,452,586)   (516,442)      
Adjustments to reconcile net loss to net cash provided by operating activities:                
Gain on investments held in Trust Account (1,090,543) 0 (1,438,875)          
Change in fair value of Forward Purchase and Backstop Securities 1,212,110 0 1,147,120          
Changes in operating assets and liabilities:                
Prepaid expenses   (880,112) 340,521   (744,542)      
Accounts payable   33,292 6,286,989   15,440      
Due to related party   0 87,410   884      
Accrued expenses - related party   20,000 0          
Accrued expenses   40,988 1,109,297   107,734      
Net cash provided by (used in) operating activities   (966,382) (920,124)   (1,136,926)      
Investing activities:                
Investment of cash into Trust Account   (235,750,000) 0   (235,750,000)      
Net cash used in investing activities   (235,750,000) 0   (235,750,000)      
Financing activities:                
Proceeds from issuance of Class B ordinary shares to Sponsor         25,000      
Proceeds from promissory note - related party   119,275 0   175,000      
Proceeds from initial public offering, net of underwriter's discount paid   225,400,000 0   225,400,000      
Proceeds from sale of Private Placement Warrants   12,350,000 0   12,350,000      
Payment of offering costs   (615,690) 0   (698,103)      
Repayment of promissory note - related party   (175,000) 0          
Proceeds from convertible promissory note   0 750,000          
Repayment of Sponsor note         (175,000)      
Deferred transaction cost payment   (615,690) 0   (698,103)      
Net cash provided by financing activities   237,078,585 750,000   237,076,897      
Net change in cash, cash equivalents and restricted cash   362,203 (170,124)   189,971      
Cash, cash equivalents and restricted cash at beginning of period   0 189,971   0      
Cash, cash equivalents and restricted cash at end of period 19,847 362,203 19,847 $ 362,203 189,971 189,971    
Supplemental disclosure of cash flow information:                
Remeasurement of Class A ordinary shares to redemption amount 1,090,544 28,307,827 1,438,875   28,593,235 $ 28,593,235    
Initial classification of the Forward Purchase and Backstop Securities   0 448,380          
Waiver of deferred underwriting commissions by underwriter $ 4,025,000 0 4,025,000          
Deferred underwriting fee payable   8,050,000 0   8,050,000      
Offering costs paid by Sponsor and included in promissory note - related party   55,725 0          
Offering costs included in accrued offering costs   1,689 0   $ 314,153      
Offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares   $ 25,000 $ 0